Primary aldosteronism and thinking/memory problems
Official title: The Association Between Primary Aldosteronism and Cognitive Dysfunction
Run by Xinjiang Medical University · NCT07304674 · Data updated 2026-11-12
This study will see if people aged 40 and older with primary aldosteronism develop memory and thinking problems over 1 to 5 years and which factors influence those changes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Xinjiang Medical University Academic / other |
| Locations | 2 sites (Chengdu, Sichuan and 1 other locations) |
| Status | Recruiting |
| Started | December 31, 2025 |
| Main results expected | December 2030 |
| Study ends | December 2031 |
| Registry record updated | January 5, 2026 |
| Trial ID | NCT07304674 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 40 or older with a biochemically confirmed diagnosis of primary aldosteronism who can complete neuropsychological testing and provide informed consent are ideal candidates.
✕Probably not a fit
Patients with major neurological or psychiatric disorders, severe sensory or motor impairments, secondary hypertension other than PA, or those unwilling or unable to consent are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational cohort follows adults with confirmed primary aldosteronism at two tertiary hospitals for up to five years. Participants complete regular standardized cognitive tests, clinical assessments, and questionnaires, with optional blood tests (including plasma neurofilament light chain) and brain MRI for some individuals. The study will determine baseline prevalence of mild cognitive impairment and dementia and track incidence of cognitive progression at 1 and 5 years while analyzing clinical and biological predictors. Researchers will compare biomarker and imaging measures between PA patients with and without baseline cognitive impairment to map cognitive trajectories and potential mechanisms.
Why it matters
Potential benefit: If successful, the results could help clinicians identify which PA patients are at higher risk for cognitive decline so they can monitor and intervene earlier.
How similar studies have gone: Prior studies have suggested cognitive changes in PA and shown promise for biomarkers like plasma NfL, but long-term prospective cohort data comparing imaging and biomarkers in PA are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Aged ≥ 40 years. * 2\. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test). * 3\. Ability to understand and cooperate with comprehensive neuropsychological assessment. * 4\. Voluntary participation and provision of written informed consent. Exclusion Criteria: * 1\. Significant visual, hearing, or motor impairment that prevents completion of cognitive testing. * 2\. History of major neurological disorders (e.g., stroke, Parkinson's disease, intracranial tumor, severe traumatic brain injury). * 3\. History of major psychiatric illness, intellectual disability, or current use of antipsychotic medications. * 4\. Diagnosis of secondary hypertension other than PA. * 5\. Unwillingness to participate by the patient or their legal representative.
Where it's running
-
The First Affiliated Hospital of Chengdu Medical College
Chengdu, Sichuan, China Recruiting -
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China Recruiting
Study contacts
- Study coordinator: Xiang Xie, PhD
- Email: xiangxie999@sina.com
- Phone: +86-991-4366892
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Aging Brain Health Initiative in Fujian
This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.
-
Photobiomodulation therapy for mild cognitive impairment and mild Alzheimer's disease
This trial tests whether daily transcranial near-infrared light therapy, versus a sham device, can improve cognitive function in adults with mild cognitive impairment or mild Alzheimer's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Structured Receptive Music to Help with Care During Bathing for People with Dementia
A structured daily music program used during hygiene care is being tested to see if it reduces refusals of care by residents with dementia in French nursing homes.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.